Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.

PPI inhibitors TEAD YAP in vivo efficacy multi-parameter optimization

Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
01 06 2023
Historique:
revised: 15 03 2023
received: 01 02 2023
medline: 5 6 2023
pubmed: 30 3 2023
entrez: 29 3 2023
Statut: ppublish

Résumé

The inhibition of the YAP-TEAD protein-protein interaction constitutes a promising therapeutic approach for the treatment of cancers linked to the dysregulation of the Hippo signaling pathway. The identification of a class of small molecules which potently inhibit the YAP-TEAD interaction by binding tightly to the Ω-loop pocket of TEAD has previously been communicated. This report details the further multi-parameter optimization of this class of compounds resulting in advanced analogs combining nanomolar cellular potency with a balanced ADME and off-target profile, and efficacy of these compounds in tumor bearing mice is demonstrated for the first time.

Identifiants

pubmed: 36988034
doi: 10.1002/cmdc.202300051
doi:

Substances chimiques

Transcription Factors 0
YAP-Signaling Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202300051

Informations de copyright

© 2023 Wiley-VCH GmbH.

Références

S. Ma, Z. Meng, R. Chen, K. L. Guan, Annu. Rev. Biochem. 2019, 88, 577-604.
S. Piccolo, S. Dupont, M. Cordenonsi, Physiol. Rev. 2014, 94, 1287-1312.
G. Halder, R. L. Johnson, Development 2011, 138, 9-22.
A. V. Pobbati, W. Hong, Theranostics 2020, 10, 3622-3635.
H. D. Huh, D. H. Kim, H−S. Jeong, H. W. Park, Cells 2019, 8, 600.
M. Santucci, T. Vignutelli, S. Ferrari, M. Mor, L. Scalvini, M. L. Bolognesi, E. Uliassi, M. P. Costi, J. Med. Chem. 2015, 58, 4857-4873.
A. V. Pobbati, B. P. Rubin, Molecules 2020, 25, 6001.
J. J. Crawford, S. M. Bronner, J. R. Zbieg, Expert Opin. Ther. Pat. 2018, 28, 867-873.
S. Kakiuchi-Kiyota, M. M. Schutten, Y. Zhong, J. J. Crawford, A. Dey, Front. Cell Dev. Biol. 2019, 7, 156.
P. Calses, J. Crawford, J. Lill, A. Dey, Trends Cancer. 2019, 5(5), 297-307.
J. Lou, Y. Lu, J. Cheng, F. Zhou, Z. Yan, D. Zhang, X. Meng, Y. Zhou, Eur. J. Med. Chem. 2022, DOI 10.1016/j.ejmech.2022.114684.
E. R. Barry, V. Simov, I. Valtingojer, O. Venier, Cells 2021, DOI 10.3390/cells10102715.
A. V. Pobbati, R, Kumar, B. P. Rubin, W. Hong, Trends Biochem. Sci. 2022, DOI 10.1016/j.tibs.2022.12.005.
C. L. Noland, S. Gierke, P. D. Schnier, J. Murray, W. N. Sandoval, M. Sagolla, A. Dey, R. N. Hannoush, W. J. Fairbrother, C. N. Cunningham, Structure 2016, 24, 179-186.
M. Sturbaut, F. Bailly, M. Coevoet, P. Sileo, M. Pugniere, M. Liberelle, R. Magnez, X. Thuru, M−C. Chartier-Harlin, P. Melnyk, M. Gelin, F. Allemand, J−F. Guichou, P. Cotelle, Eur. J. Med. Chem. 2021, DOI 10.1016/j.ejmech.2021.113835.
F. Gibault, M. Sturbaut, M. Coevoet, M. Pugniere, A. Burtscher, F. Allemand, P. Melnyk, W. Hong, B. P. Rubin, A. V. Pobbati, J-F. Guichou, P. Cotelle, F. Bailly, ChemMedChem 2021, 16, 2823-2844.
J. Kim, H. Lim, S. Moon, S. Y. Cho, M. Kim, J. H. Park, H. W. Park, K. T. No, Cancers 2021, DOI 10.3390/cancers13164246.
S. A. Smith, R. B. Sessions, D. K. Shoemark, C. Williams, R. Ebrahimighaei, M. C. McNeill, M. P. Crump, T. R. McKay, G. Harris, A. C. Newby, M. Bond, J. Med. Chem. 2019, 62, 1291-1305.
P. Furet, V. Bordas, M. Le Douget, B. Salem, Y. Mesrouze, P. Imbach-Weese, H. Sellner, M. Voegtle, N. Soldermann, E. Chapeau, M. Wartmann, C. Scheufler, C. Fernandez, J. Kallen, V. Guagnano, P. Chène, T. Schmelzle, ChemMedChem 2022, DOI 10.1002/cmdc.202200303.
Novartis. Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors. WO2021186324, 2021.
F. Bokhovchuk, Y. Mesrouze, C. Delaunay, T. Martin, F. Villard, M. Meyerhofer, P. Fontana, C. Zimmermann, D. Erdmann, P. Furet, C. Scheufler, T. Schmelzle, P. Chène, Protein Sci. 2020, 29, 509-520.
J. C. Hau, D. Erdmann, Y. Mesrouze, P. Furet, P. Fontana, C. Zimmermann, T. Schmelzle, F. Hofmann, P. Chène, T. Schmelzle, ChemBioChem 2013, 14, 1218-1225.
M. Basilaia, M. H. Chen, J. Secka, J. L. Gustafson, Acc. Chem. Res. 2022, DOI 10.1021/acs.accounts.2c00500.
 
I. D. Kuntz, K. Chen, K. A. Sharp, P. A. Kollman, Proc. Natl. Acad. Sci. USA 1999, 96, 9997-10002;
A. L. Hopkins, C. R. Groom, A. Alex, Drug Discovery Today 2004, 9, 430-431;
C. Abad-Zapatero, J. T. Metz, Drug Discovery Today 2005, 10, 464-469.
M. C. Sanguinetti, M. Trustani-Firouzi, Nature 2006, 440, 463-460.
B. M. Dumotier, Heart 2014, 100, 1907-1915.
G. Erdemli, A. M. Kim, H. Ju, C. Springer, R. C. Penland, P. K. Hoffmann, Front. Pharmacol. 2012, DOI 10.3389/fphar.2012.00006.
Y. Mesrouze, M. Meyerhofer, F. Bokhovchuk, P. Fontana, C. Zimmermann, T. Martin, C. Delaunay, A. Izaac, J. Kallen, T. Schmelzle, D. Erdmann, P. Chène, Protein Sci. 2017, 26, 2399-2409.
Novartis. Phenoxyphenylthioalkanecarboxylic acid amides and their use as herbicides and plant growth regulants. US 4,349,377, 1982. MPB-1 corresponds to the corresponding free acid of Example 5.
C. Vonrhein, C. Flensburg, P. Keller, A. Sharff, O. Smart, W. Paciorek, T. Womack, G. Bricogne, Acta Crystallogr. 2011, D67, 293-302.
I. C. Vonrhein, I. J. Tickle, C. Flensburg, P. Keller, W. Paciorek, A. Sharff, G. Bricogne, Acta Cryst. 2018, DOI 10.1107/S010876731809640X..
A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, J. Appl. Crystallogr. 2007, 40, 658-674.
P. Emsley, K. Cowtan, Acta Crystallogr. 2004, D60, 2126-2132.
G. Bricogne, E. Blanc., M. Brandl, C. Flensburg, P. Keller, W. Paciorek, P. Roversi, A. Sharff, O. S. Smart, C. Vonrhein, T. O. Womack, 2017, Cambridge, United Kingdom: Global Phasing Ltd.

Auteurs

Holger Sellner (H)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Emilie Chapeau (E)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Pascal Furet (P)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Markus Voegtle (M)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Bahaa Salem (B)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Mickaël Le Douget (M)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Vincent Bordas (V)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Jean-Marc Groell (JM)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Anne-Laure Le Goff (AL)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Christine Rouzet (C)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Thomas Wietlisbach (T)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Thomas Zimmermann (T)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Joseph McKenna (J)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Cara E Brocklehurst (CE)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Patrick Chène (P)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Markus Wartmann (M)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Clemens Scheufler (C)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Joerg Kallen (J)

Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Gareth Williams (G)

Pharmacokinetics Sciences, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Stephanie Harlfinger (S)

Pharmacokinetics Sciences, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Martin Traebert (M)

Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Bérengère M Dumotier (BM)

Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Tobias Schmelzle (T)

Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Nicolas Soldermann (N)

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH